STOCK TITAN

Beam Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Beam Therapeutics Inc. (Nasdaq: BEAM) will have its CEO, John Evans, participate in a fireside chat at the Chardan Virtual 5th Annual Genetic Medicines Conference on Oct. 5, 2021, at 8:00 a.m. ET. The event will be streamed live and accessible through the investor section of Beam's website, where it will remain archived for 60 days. Beam Therapeutics is focused on precision genetic medicines using innovative base editing technology, aimed at developing effective treatments while maintaining a commitment to cutting-edge science and patient care.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, Oct. 5, 2021 at 8:00 a.m. ET.

The live webcast will be available in the investor section of the company's website at www.beamtx.com. The webcast will be archived for 60 days following the presentation.

About Beam Therapeutics

Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Contacts:

Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

Media:
Dan Budwick
1AB
dan@1abmedia.com


FAQ

When is Beam Therapeutics' fireside chat at the Chardan Conference?

The fireside chat will take place on Oct. 5, 2021, at 8:00 a.m. ET.

Where can I watch the Beam Therapeutics webcast?

The webcast can be viewed in the investor section of Beam's website at www.beamtx.com.

What technology does Beam Therapeutics use for genetic medicines?

Beam Therapeutics utilizes base editing technology for developing precision genetic medicines.

What is the focus of Beam Therapeutics?

Beam Therapeutics is focused on creating precision genetic medicines and advancing various base editing programs.

How long will the webcast of the Beam Therapeutics presentation be available?

The webcast will be archived for 60 days following the presentation.

Beam Therapeutics Inc.

NASDAQ:BEAM

BEAM Rankings

BEAM Latest News

BEAM Stock Data

2.27B
81.62M
1.42%
93.14%
14.45%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CAMBRIDGE